JP2022551282A5 - - Google Patents
Info
- Publication number
- JP2022551282A5 JP2022551282A5 JP2022520724A JP2022520724A JP2022551282A5 JP 2022551282 A5 JP2022551282 A5 JP 2022551282A5 JP 2022520724 A JP2022520724 A JP 2022520724A JP 2022520724 A JP2022520724 A JP 2022520724A JP 2022551282 A5 JP2022551282 A5 JP 2022551282A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteine
- approximately
- composition according
- absent
- valine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025107100A JP2025144567A (ja) | 2019-10-04 | 2025-06-25 | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2019-0123250 | 2019-10-04 | ||
| KR20190123250 | 2019-10-04 | ||
| PCT/KR2020/013467 WO2021066600A1 (ko) | 2019-10-04 | 2020-10-05 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107100A Division JP2025144567A (ja) | 2019-10-04 | 2025-06-25 | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551282A JP2022551282A (ja) | 2022-12-08 |
| JP2022551282A5 true JP2022551282A5 (enExample) | 2023-10-16 |
| JP7761557B2 JP7761557B2 (ja) | 2025-10-28 |
Family
ID=75338451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520724A Active JP7761557B2 (ja) | 2019-10-04 | 2020-10-05 | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 |
| JP2025107100A Abandoned JP2025144567A (ja) | 2019-10-04 | 2025-06-25 | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107100A Abandoned JP2025144567A (ja) | 2019-10-04 | 2025-06-25 | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230000950A1 (enExample) |
| EP (1) | EP4043026A4 (enExample) |
| JP (2) | JP7761557B2 (enExample) |
| KR (1) | KR20210040818A (enExample) |
| CN (1) | CN114786706B (enExample) |
| WO (1) | WO2021066600A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220050820A (ko) | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| US20240197834A1 (en) * | 2021-04-09 | 2024-06-20 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN116120403B (zh) * | 2022-11-01 | 2026-03-17 | 成都普康唯新生物科技有限公司 | 一种固相制备Tirzepatide的方法 |
| CN117756913B (zh) * | 2022-11-07 | 2025-05-09 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
| CN116942612A (zh) * | 2023-08-30 | 2023-10-27 | 重庆派金生物科技有限公司 | 一种脂肪酸修饰的胰高血糖素样肽类似物的鼻用喷雾剂及其应用 |
| WO2025101959A1 (en) * | 2023-11-08 | 2025-05-15 | Renbio, Inc. | Plasmid dna constructs for peptide hormone expression |
| KR20250177375A (ko) * | 2024-06-13 | 2025-12-23 | 한미약품 주식회사 | Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| WO2011075393A2 (en) * | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| CA2929459C (en) * | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| EP3080154B1 (en) * | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| AR103242A1 (es) * | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| FI3322437T3 (fi) * | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| JP6712323B2 (ja) * | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| CN122440793A (zh) * | 2016-06-29 | 2026-07-24 | 韩美药品株式会社 | 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途 |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| AR110301A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| WO2020071865A1 (ko) * | 2018-10-04 | 2020-04-09 | 한미약품 주식회사 | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 |
-
2020
- 2020-10-05 JP JP2022520724A patent/JP7761557B2/ja active Active
- 2020-10-05 KR KR1020200128260A patent/KR20210040818A/ko active Pending
- 2020-10-05 US US17/766,137 patent/US20230000950A1/en active Pending
- 2020-10-05 CN CN202080083888.3A patent/CN114786706B/zh active Active
- 2020-10-05 EP EP20872428.6A patent/EP4043026A4/en active Pending
- 2020-10-05 WO PCT/KR2020/013467 patent/WO2021066600A1/ko not_active Ceased
-
2025
- 2025-06-25 JP JP2025107100A patent/JP2025144567A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6694013B2 (ja) | オキシントモジュリンと免疫グロブリンのフラグメントとを含むタンパク質結合体の液状製剤 | |
| JP6936366B2 (ja) | 胆汁酸に関係した障害の治療方法 | |
| JP7322105B2 (ja) | 免疫グロブリンＦｃフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法 | |
| RU2671088C2 (ru) | Агонисты рецепторов глюкагона/glp-1 для лечения ожирения | |
| JP6898231B6 (ja) | Ｇｉｐアゴニスト化合物及び方法 | |
| JP7761557B2 (ja) | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 | |
| TWI708614B (zh) | 包含調酸素衍生物之治療高血脂症的組成物 | |
| JP2021518745A5 (ja) | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2025114622A (ja) | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 | |
| JP2022509568A5 (enExample) | ||
| JP2018526333A5 (enExample) | ||
| JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
| CN107849110A (zh) | 选择性pyy化合物及其用途 | |
| CN104302772A (zh) | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 | |
| JP2015504073A5 (enExample) | ||
| JP2018504901A5 (enExample) | ||
| TWI889865B (zh) | 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途 | |
| JP2025178483A (ja) | ポリペプチドを含む医薬組成物 | |
| JP2018505153A (ja) | グルカゴン誘導体 | |
| JP2023538236A5 (enExample) | ||
| JP2022535685A (ja) | ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物 | |
| JP2013511287A (ja) | ポリペプチド・コンジュゲート | |
| IL299778A (en) | Therapeutic use of glucagon derivative or conjugate thereof for liver disease | |
| JP2024512895A5 (enExample) | ||
| JP2025500508A5 (enExample) |